Bristol-Myers Squibb Company News - October 12, 2026
Bristol Myers Squibb Reports Admilparant Win at 60 mg for Lung Scarring
Bristol Myers Squibb announced positive topline results from its pivotal Phase 3 trial of experimental drug admilparant in patients with idiopathic pulmonary...
Bristol Myers Squibb Reports RYZ101 Improves Progression-Free Survival in Phase 3 Trial
Bristol Myers Squibb announced positive topline results from ACTION-1, a Phase 3 study of its radiopharmaceutical therapy RYZ101. The trial evaluated the drug...
🟢 Bristol-Myers Squibb is trading 6% up in pre-market
Bristol-Myers Squibb is trading 6.17% higher at $62.77, with no verified company-specific catalyst identified for the October 12 pre-market rise. - Coverage...